ORIC Pharmaceuticals, Inc.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is dedicated to discovering, developing, and commercializing innovative therapies to address cancer resistance. Their mission is to improve patients' lives by targeting resistance mechanisms, making existing cancer therapies more effective and longer-lasting.

Products & Services

ORIC-944:A drug candidate in Phase 1b study for prostate cancer, used in combination with AR inhibitors.

Specialties

Cancer Resistance Mechanisms Oncology Drug Development Innate Resistance Acquired Resistance Bypass Resistance

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 125000000 MR: - FA: $125 million FAN: 125000000	D: 2025-05-28 FD: 2025-05-28	8 investors
2	RT: Private Placement T: - FT: Private Placement	A: 125000000 MR: - FA: 125 million FAN: 125000000	D: 2024-01-22 FD: 2024-01-22	6 investors
3	RT: Private Placement T: - FT: Private Placement	A: 85000000 MR: - FA: $85 million FAN: 85000000	D: 2023-06-26 FD: 2023-06-26	5 investors

Private Placement Latest

2025-05-28

$125.0M

8 investors (Pro only)

Private Placement 2024-01-22

$125.0M

Private Placement 2023-06-26

$85.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jacob Chacko

President, Chief Executive Officer and Board Member

L

Lori Friedman

Chief Scientific Officer

P

Pratik Multani

Chief Medical Officer

M

Matthew Panuwat

Chief Business Officer

D

Dominic Piscitelli

Chief Financial Officer

C

Christian V. Kuhlen

General Counsel

View 13 more team members with Pro

Unlock Full Team Directory

Recent News